Evidence map›Paper›PMID 15526059›Full record

Trial reportPLoS medicine2004

Limited durability of viral control following treated acute HIV infection.

Daniel E Kaufmann, Mathias Lichterfeld, Marcus Altfeld, Marylyn M Addo, Mary N Johnston, Paul K Lee, Bradford S Wagner, Elizabeth T Kalife, Daryld Strick, Eric S Rosenberg and 1 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 176 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Review
  14. CD8Frontiers in immunology · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. HIV-1 Eradication: Early Trials (and Tribulations).Trends in molecular medicine · 2016
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Daniel E KaufmannPartners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mathias Lichterfeld
Marcus Altfeld
Marylyn M Addo
Mary N Johnston
Paul K Lee
Bradford S Wagner
Elizabeth T Kalife
Daryld Strick
Eric S Rosenberg
Bruce D Walker
Harvard University · USMassachusetts General Hospital · USHoward Hughes Medical Institute · US

Funding

NATURAL HISTORY OF AIDS IN HOMOSEXUAL MENU01AI035040 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DETELS, ROGER, MARTINEZ-MAZA, OTONIEL · 1993 to 2018
$75.2M
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
MULTICENTER AIDS COHORT STUDYU01AI035039 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WOLINSKY, STEVEN M · 1993 to 2018
$66.4M
Multicenter Aids Cohort Study- Part B (Baltimore Site)U01AI035042 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BROWN, TODD T, MARGOLICK, JOSEPH B. · 1993 to 2018
$61.5M
ZINC AND CA EDTA THERAPY OF PLUMBISMM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · PI BELCHER, HAROLYN MILLICENT EDITH · 1985 to 2007
$37.3M
METHODOLOGICAL EXPERTISE IN INTREPRETING MACS DATAU01AI035043 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACOBSON, LISA P · 1993 to 2011
$26.9M
CTL Responses to Regulatory and Accessory HIV-1 ProteinsR01AI050429 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTFELD, MARCUS · 2002 to 2011
$3.7M
MULTICENTER AIDS COHORT STUDY PATHOGENESIS RESEARCH LABSU01AI037613 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1995 to 2003
$3.4M
MULTICENTER AIDS COHORT STUDY PATHOGENESIS RESEARCHU01AI037984 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARGOLICK, JOSEPH B. · 1995 to 2003
$3.1M
IMMUNE CONTROL OF HIV REPLICATIONR01AI044656 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1999 to 2003
$2.8M
NCRR NIH HHS 5-M01-RR-00052NCRR NIH HHS M01 RR000052NIAID NIH HHS R01 AI044656NIAID NIH HHS R01 AI050429NIAID NIH HHS R01 AI 29568NIAID NIH HHS R01 AI 44656NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035040NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI035043NIAID NIH HHS U01 AI037613NIAID NIH HHS U01 AI037984NIAID NIH HHS UO1-AI-35039NIAID NIH HHS UO1-AI-35040NIAID NIH HHS UO1-AI-35041NIAID NIH HHS UO1-AI-35042NIAID NIH HHS UO1-AI-35043NIAID NIH HHS UO1-AI-37613NIAID NIH HHS UO1-AI-37984
6 · The paper itself

Abstract

backgroundEarly treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. METHODS AND

findingsFourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria.

conclusionsThese data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve.

Indexed as

Antiretroviral Therapy, Highly ActiveAcute DiseaseAdultDrug Administration ScheduleFemaleHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedTreatment OutcomeViremia

Identifiers

PMID15526059
PMCPMC524377
OpenAlexW2106336618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.